Cardiovascular
P2Y12 receptor antagonists
Antiplatelet drugs that block the ADP receptor on platelets; given with aspirin in acute coronary syndromes and after coronary stenting.
آلية العمل
- ADP binding to the P2Y12 receptor on platelets activates the glycoprotein IIb/IIIa receptors that let platelets bind fibrinogen and stick to one another.
- These drugs stop ADP binding to P2Y12, so GP IIb/IIIa is not activated and aggregation is blocked, by a different route from aspirin.
- Ticagrelor and cangrelor bind reversibly; clopidogrel, prasugrel and ticlopidine bind irreversibly.
- Onset differs widely: minutes for intravenous cangrelor, hours for ticagrelor and prasugrel, days for clopidogrel unless a loading dose is given.
الأهداف الجزيئية
- P2Y12 ADP receptor on platelets: Antagonist (reversible or irreversible, by drug)
أدوية P2Y12 receptor antagonists
Thienopyridines (irreversible)
- Clopidogrel (A prodrug activated by CYP2C19.)
- Prasugrel
- Ticlopidine (Kept for patients who cannot take the others, because of serious blood disorders.)
Non-thienopyridines (reversible)
- Ticagrelor (Reversible.)
- Cangrelor (Intravenous, used during PCI.)
الاستخدامات العلاجية
- Acute coronary syndromes, with aspirin
- Preventing thrombosis around percutaneous coronary intervention and stents
- Preventing atherosclerotic events after a recent myocardial infarction or stroke, and in peripheral arterial disease (clopidogrel)
الأمراض التي يعالجها
الحرائك الدوائية
- Clopidogrel only works once CYP2C19 has converted it to its active metabolite; people who are poor metabolisers get less effect and should be given prasugrel or ticagrelor instead.
الآثار الجانبية
- Bleeding, which can be prolonged and has no antidote
- Thrombotic thrombocytopenic purpura (reported with clopidogrel and prasugrel)
- Ticlopidine: agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anaemia
موانع الاستعمال حسب الحالة
- Peptic ulcer disease (ممنوع): Blocking platelet activation prevents the platelet plug that stops bleeding.
- Previous stroke or transient ischaemic attack (prasugrel) (ممنوع): Prasugrel increased bleeding inside the skull in these patients.
محاذير وتداخلات أخرى
- Omeprazole and esomeprazole inhibit CYP2C19 and weaken clopidogrel: avoid the combination.
- Ticagrelor works less well with aspirin doses above 100 mg.
موضوعات مرتبطة
مكتوب من
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 21, Anticoagulants and Antiplatelet Agents, IV.B P2Y12 receptor antagonists
مرجع تعليمي، وليس استشارة طبية أو تشخيصاً أو علاجاً.